Grants for HIV / AIDS

NOTE: Gilead accepts grant applications year-round, meaning your organization may apply whenever you’re ready. Keep in mind that you must submit the application at least 6 weeks before your activity begins, and that it typically takes about 6 to 12 weeks for us to review it. 

What We Fund

Gilead welcomes funding requests for innovative, high impact projects that relate to at least one of our core therapeutic areas:

• HIV
• Liver disease
  • HCV
  • HBV
  • HDV
• Oncology
  • Hematology
  • Solid tumors
• Inflammatory and respiratory diseases

We consider a number of factors when reviewing grant requests, but it is most important for applications to demonstrate a strong commitment to — and capacity for — delivering the specific services your funded grant would support.

Types of Organizations We Support

Patient Community Support:

Lack of awareness is often a significant barrier to disease screening and treatment — especially among at-risk populations — leading to acute disparities in care. Gilead supports patients and their communities by funding a variety of awareness-raising projects.

Examples of Patient Community Support projects Gilead has funded include:

• Events or resources to educate patients about prevention and care options, such as:
  • Presentations
  • Web-based resources
  • Printed materials
  • Testing and screening initiatives
• The types of Patient Community Support organizations Gilead has funded include:
  • Patient advocacy and support groups
  • Hospitals and clinics
  • Nonprofit service organizations
  • Professional associations
  • Academic medical centers and universities

Medical & Scientific Support:

Ongoing education is essential to ensuring that healthcare professionals can continue to deliver the best possible care based on the latest advances in medicine. Gilead supports high-impact, continuing medical education programs that expand the knowledge and skills of healthcare professionals.

Gilead has funded a range of Medical and Scientific Support projects, including:

• Continuing medical education (CME) accredited by ACCME or another relevant organization
• Non-accredited CME in compliance with FDA guidelines
• Scientific conferences
• Lecture series or symposia

Please remember that attendance at Medical and Scientific Support events should be open to professionals in the community. The principal speaker may not be employed by, or the audience limited to, the funded organization.

The types of Medical and Scientific Support organizations Gilead has funded include:

• Medical universities
• Professional associations
• Community health centers
• Hospitals and academic medical centers

If you represent an accredited medical education program that involves for-profit medical education companies or that has a national or regional scope (e.g., satellite symposia at scientific conferences), Gilead offers a separate application and review process managed by the Gilead Independent Medical Education Department (IMED).

Gilead North America Grants

Gilead is inspired by the work that our grantees do every day to improve access and eliminate barriers to healthcare, and advance education among patients and healthcare professionals. Gilead supports projects across all of our therapeutic areas — HIV, liver diseases, hematology and oncology, and inflammatory and respiratory diseases.

Focus Areas

HIV:

Continual advances in medical research help millions of people living with HIV have longer, more fulfilling lives today. But HIV continues to have a devastating impact, especially on people who belong to underserved communities and who lack access to medical care. Gilead supports organizations working to help individuals learn their status and get the care they need. We also support organizations that aim to solve the challenges of tomorrow, including how to:

• Understand the impact HIV has on an aging population
• Ensure continuity and retention in care
• Spark appreciation for innovative thinking in HIV treatment
• Identify and create a new generation of advocates

HIV Cure:

Gilead works to address the HIV epidemic by discovering transformative and life-saving medicines, developing simplified treatment regimens that increase efficacy, expanding access to treatment for those who need it most and building communities among people affected by HIV and AIDS. Continuing on this commitment, Gilead will partner with and support institutions, community groups and organizations that are engaged in HIV cure activities by providing grant funding.

HIV Prevention:

More tools than ever are now available to help prevent HIV infection. Yet about 40,000 new cases of HIV are still reported in the U.S. each year. Gilead supports the efforts of community-based organizations, public health entities and similar nonprofit organizations to educate their constituents about comprehensive HIV prevention, including the role of pre-exposure prophylaxis (PrEP). Specifically, Gilead supports programs designed to:

• Provide comprehensive education on the range of prevention options and strategies available
• Ensure biomedical prevention plans, such as PrEP, are implemented safely and effectively in accordance with recommended guidelines
• Engage communities and individuals at highest risk for HIV infection in prevention efforts

Liver Disease:

Each year, more Americans die from Hepatitis C than HIV. Yet public awareness of this disease remains limited because of its disproportionate impact on drug users, minorities and other at-risk groups. Gilead is working to change this by funding organizations that raise awareness of the importance of testing and access to care among these groups, as well as those that:

• Look for ways to increase treatment capacity and sustainability
• Move individuals down the care pathway from screening to cure
• Eliminate intrinsic barriers to care and treatment

Hematology & Oncology:

Most adults in the U.S. have met or have known at least one cancer victim or survivor. Cancer remains one of the greatest health challenges we face, especially as the population ages. While there is no cure yet, education and awareness are powerful tools for detecting and treating the disease, and Gilead supports organizations that work to:

• Improve health literacy, enabling individuals affected by cancer to make informed health decisions
• Educate healthcare providers on identification, screening and diagnosis
• Improve access to treatment by overcoming financial and other obstacles

Inflammatory and Respiratory Diseases:

From cystic fibrosis (CF) to influenza, inflammatory and respiratory diseases have a substantial impact on people of every age, gender, ethnic group and economic class. Gilead funds organizations that work in this therapeutic area to:

• Improve individuals’ health literacy, enabling them to make informed health decisions
• Educate healthcare providers on identification, screening and diagnosis
• Improve access to treatment by overcoming financial and other obstacles

Funding

There are no minimum or maximum request amounts. Applicants should request the level of funding that is required based on programmatic needs.

NOTE: There are no formal application deadlines. The Foundation’s Board of Trustees reviews all applications at its quarterly meetings. Applicants should be prepared to wait several weeks or months for a decision.

About

Robert Mapplethorpe established the Robert Mapplethorpe Foundation on May 27, 1988, the year before his death, to protect his work, to advance his creative vision and to promote the causes he cared about. Serving as the first president of its board of trustees, he established two mandates: to promote photography as an art form in order to achieve its recognition and respect at the same level as painting and sculpture; and to support HIV/AIDS medical research. In keeping with Mapplethorpe's wishes, The Robert Mapplethorpe Foundation continues to support photography programming at both major museums as well as small institutions for exhibitions, acquisitions, and publications.

In 1993, the Foundation provided an historic gift to the Solomon R. Guggenheim Foundation to create the named Robert Mapplethorpe Gallery and to inaugurate the Guggenheim Museum's photography program. In addition to its financial component, the Foundation made a gift of more than 200 of the artist’s works, selected by the Museum.

The Foundation subsequently awarded three major gifts supporting photography programs which resulted in galleries or facilities permanently named for Robert Mapplethorpe—at the Whitney Museum of American Art, the Hessel Museum of Art at Bard College, in Annandale-on-Hudson, NY, and the National Portrait Gallery, part of the National Galleries of Scotland in Edinburgh. In addition to the Guggenheim Museum, significant public collections of Mapplethorpe’s work may be found in the Artist Rooms Collection jointly owned by the Tate Modern, London and the National Galleries of Scotland; at the Museum of Modern Art, New York; the Hessel Museum of Art; and the Kinsey Institute at Indiana University.

In 2011, the Mapplethorpe Foundation donated its archive to the Getty Research Institute and gave an encyclopedic collection of artworks to the J. Paul Getty Museum in partnership with the Los Angeles County Museum of Art. This gift established a comprehensive archive and collection available to scholars.

In its early years, the Foundation prioritized its focus on HIV and AIDS medical research. It created important medical facilities and programs, including the Robert Mapplethorpe Laboratory for AIDS Research at Harvard Medical School in Boston, the Robert Mapplethorpe Residential Treatment Facility at Beth Israel Medical Center in New York, and the Robert Mapplethorpe Center for HIV Research at St. Vincent's Hospital, New York. The Foundation provided substantial financial support to the American Foundation for AIDS Research (amfAR). The Foundation continues to support research initiatives and has provided funds to amfAR, distinguished institutions such as the Rockefeller University, and community-based experimental treatment organizations, including the AIDS Community Research Initiative of America (ACRIA).

The Foundation is dedicated to protecting and expanding Mapplethorpe’s artistic legacy by encouraging museum exhibitions internationally. It publishes books and places his artworks from its considerable inventory in important public and private collections around the world.

Photography Grant

As the beneficiary of Robert Mapplethorpe’s Estate, the Foundation has made contributions in the form of artworks or gifts of money to qualifying applicants. In the appropriate circumstance, the Foundation will also assist independent curators in developing interesting photography exhibitions.

NOTE: Proposals are accepted on a rolling basis. Applicants are encouraged to submit proposals by July 7, 2022. For those requesting support for special events, proposals must be received at least six weeks prior to the scheduled event.

Positive Action Community Grants

ViiV Healthcare was established to take an innovative approach to the challenge of HIV—and we do. It’s who we are. An innovative approach means we go beyond developing new medicines—we know it takes more to end the epidemic.

Through a combination of community-focused approaches that include deep listening, grantmaking, community engagement, shared learning, and cultural arts programs, we ensure that the voices of the HIV community inform everything we do.

Focus

Our approach to giving has always been about more than money. We Listen. Seeking insights and understanding to foster collaboration and action. We Activate new initiatives and fund community projects where there are the greatest disparities, while connecting individuals and organizations to strengthen networks and services. We Amplify. Sharing insights to illuminate bright spots and drive community solutions. We Sustain. Strengthening leaders, organizations, and communities to build and expand on the momentum of effective work. Through this approach we focus our funding and collaborations on community organizations that are prioritizing work in three key focus areas:

Networks

Strengthen supportive networks for people living with an impacted by HIV and those who serve them

Linkage & Engagement

Support navigation and programs that help link, re-link, and engage people in HIV prevention, treatment, and care

Advocacy

Amplify the efforts of people living with and impacted by HIV to advocate for themselves, strengthen leadership, insights, and culture activities that reduce stigma, and fuel community responses.

Funding

ViiV Healthcare’s Positive Action Community Grants (PACG) initiative is currently requesting proposals to support:

• The health and well-being of people living with HIV through innovative, community-led solutions that address disparities in the epidemic, and;
• Strong prevention infrastructure for communities of color, fueling new ways to reach and engage people in HIV prevention, shift the narrative around risk, and fuel networks that help disrupt disparities in HIV prevention.

Organizations applying to Positive Action Community Grants may request funding in the following three categories:

• General operating support for core support and mission-driven community-based work.
• Special events sponsorships for conferences and events that foster networks, create awareness, and amplify the voices of people living with HIV and AIDS.
• Project support for organizations implementing innovative projects within ViiV Healthcare’s focus areas: linkage to care, networks of support, and advocacy. ViiV Healthcare is particularly interested in efforts that operate at the intersection of HIV, stigma, and other social determinants of health in the following ways:
  • Expanding harm reduction services and advocacy to successfully engage people who use drugs in care, and support their families and communities;
  • The decriminalization of HIV at the local and national level;
  • Increasing access to quality and culturally responsive sexual health education;
  • Activating arts and culture as a tool for community engagement, connection, and building empathy;
  • Increasing access to and awareness of the mental health needs of people living with or vulnerable to HIV.

NOTE: All applications are due by 5:00 PM local time of applicant organization.

The purpose of this Funding Opportunity Announcement (FOA) is to support translation of advanced HIV-1 vaccine candidates from pre-clinical studies through different phases of process and product development, Current Good Manufacturing Practice (CGMP) manufacturing and regulatory filing to the point of clinical testing. The FOA will support technology transfer, preclinical immunogenicity and optimization studies, process development, analytical assay development, qualification, validation, testing, small scale pilot or engineering runs, CGMP manufacture in partnership with Pharma/Biotech/Contract Manufacturing Organizations (CMO), quality assurance/quality control oversight, fill-finish activities, product release and storage, generation of reference standard, drug substance and drug product stability testing programs, Investigational New Drug (IND)-enabling studies, regulatory submission preparation.

Application budgets are limited to $3,000,000 direct costs per year for the 1st and 2nd years of award. 

NOTE: The following deadlines apply to standard grant applications (due by 5:00 pm  local time of applicant organization):

• February 16, 2023
• June 16, 2023
• October 16, 2023
• February 16, 2024
• June 16, 2024
• October 16, 2024
• February 16, 2025
• June 16, 2025
• October 16, 2025

Deadlines for AIDS-related projects are the following (due by 5:00 pm local time of applicant organization):

• March 16, 2023 
• July 16, 2023
• November 16, 2023
• March 16, 2024
• July 16, 2024
• November 16, 2024
• March 16, 2025
• July  16, 2025
• November 16, 2025

The purpose of this Funding Opportunity Announcement (FOA) is to enhance mechanistic and epidemiologic investigations addressing the roles of co-infection and cancer to shed light on presently unestablished pathways in carcinogenesis that may inform prevention and treatment strategies for infection-related cancers. Co-infection is defined as the occurrence of infections by two or more infectious (pathogenic or non-pathogenic) agents either concurrently or sequentially and includes both acute and chronic infections by viruses, bacteria, parasites, and/or other microorganisms. Preference will be given to investigations of co-infections with known oncogenic agents (excluding human immunodeficiency virus [HIV]) and of co-infections that engender novel opportunities for prevention and treatment.

The Kent Richard Hofmann Foundation is a private foundation dedicated to the fight against HIV and AIDS.

Grants are made semi-annually, to community-based organizations, in support of:

• Care and direct services
• Education
• Research

Grants are made to support developing or established programs, with emphasis on direct benefit to clients or target audiences. Requests from throughout the US are considered, with a particular interest in smaller communities and rural areas.

Previous requests receiving serious consideration have included:

• Requests from locations with a scarcity of available funding;
• Requests for seed money for new projects, programs, or structures;
• Innovative ideas for meeting standard needs.

This Funding Opportunity Announcement (FOA) supports research from creative early stage investigators who propose highly innovative, pioneering studies with potential to open new areas of HIV/AIDS related to coinfections, comorbidities, and complications. Projects should reflect new and novel scientific directions that are distinct from concepts and approaches being pursued in the investigators research program or elsewhere. Projects must be consistent the scientific priorities outlined by the NIH Office of AIDS Research (OAR). These priorities have been most recently been described in NOT-OD-20-018.

NOTE: All applications are due by 5:00 PM local time of applicant organization. 

Through this funding opportunity announcement, the National Cancer Institute (NCI) intends to focus on the biological interactions of cancer health disparities in people living with HIV (PLWH) from underrepresented minority groups through basic mechanistic or translational studies to investigate how HIV interacts with health disparities to promote both non-AIDS and AIDS-defining cancer initiation, progression, and the resulting pathogenic disease sequelae.

Through this funding opportunity announcement, the National Cancer Institute (NCI) intends to focus on the biological interactions of cancer health disparities in people living with HIV (PLWH) from underrepresented minority groups through basic mechanistic or translational studies to investigate how HIV interacts with health disparities to promote both non-AIDS and AIDS-defining cancer initiation, progression, and the resulting pathogenic disease sequelae.